A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Gynecologic Cancer|Breast Cancer|Colorectal Cancer|Gastric Adenocarcinoma|Lung Adenocarcinoma|Pancreatic Cancer|Head and Neck Cancer
Interventions: DRUG: PY159 Single agent dose level 1|DRUG: PY159 Single agent dose level 2|DRUG: PY159 Single agent dose level 3|DRUG: PY159 Single agent dose level 4|DRUG: PY159 Single agent dose level 5|DRUG: PY159 Single agent dose level 6|DRUG: PY159 Single agent dose level 7|DRUG: PY159/Pembrolizumab Combination dose level 1|DRUG: PY159/Pembrolizumab Combination dose level 2|DRUG: PY159/Pembrolizumab Combination dose level 3|DRUG: PY159/Pembrolizumab Combination dose level 4|DRUG: PY159 Single agent dose expansion cohort|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 1|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 2|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 3|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 4|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 5|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 6
Sponsor: Pionyr Immunotherapeutics Inc.